Jonathan Strober, MD, discusses promising results from the VIBRANCE-MG trial, highlighting nipocalimab's safety and efficacy for pediatric myasthenia gravis.
Regeneron could be just a few months away from filing for approval of a therapy for the neuromuscular disorder generalised myasthenia gravis (gMG), cemdisiran, which can be dosed just four times a ...
Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis. In ...
Highlights from the 2025 Muscular Dystrophy Association (MDA) Conference include clinical updates, expert insights, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback